Results from the phase 3 QuANTUM-First trial have the potential to change standard care for adults with newly diagnosed FLT3-ITD+ acute myeloid leukemia, according to the lead study author.
Researchers sought to determine whether ASTX727 with venetoclax would be effective in patients with AML.
Researchers sought to determine whether TP53 mutations would be linked with more aggressive disease in patients with MDS or AML.
Researchers sought to determine the impact of body changes on pediatric patients who undergo treatment for AML.
A retrospective analysis sought to determine the real world outcomes for patients with AML treated with venetoclax and azacitidine or decitabine.
The approval was based on data from the phase 3 AGILE trial.
Researchers sought to compare upfront azacitidine and decitabine in a retrospective study of patients with acute myeloid leukemia.
Survival for adolescent and young adult leukemia survivors remained below general population at up to 30 years of follow-up.
A retrospective study sought to determine the response to azacitidine in patients with CMML applying the overlap MDS/MPN response criteria.
A phase 3 trial evaluating ivosidenib plus azacitidine in adults with previously untreated IDH1-mutated AML showed that it met all endpoints.
